Servier Pharmaceuticals is providing innovative therapeutics to patients with serious unmet medical requriements. They have approved products for Acute Myeloid Leukemia (AML) and Cholangiocarcinoma.
Ikris Pharma Network is authorized by Servier Pharmaceuticals to provide access to their drugs to Indian patients through Named-patient Import.
Servier Products
Tibsovo®
Tibsovo (Ivosidenib) was approved by the FDA in 2018 and Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients of Acute Myeloid Leukemia (AML) and Locally Advanced or Metastatic Cholangiocarcinoma. Ivosidenib is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme.
Tibsovo at a glance
- Tibsovo Tablets approved in multiple countries..
- Tibsovo was first approved in the United States.
- Commercialized by Servier Pharmaceuticals LLC.
- Approved for Acute Myeloid Leukemia and Cholangiocarcinoma.
Please click on the link for additional information or visit the following website https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf.
